TRIANA's 'Molecular Glue' Drug Enters Trials for Resistant Lung Cancer

LEXINGTON, MA – March 19, 2026 – In a significant step forward for oncology, TRIANA Biomedicines has announced the dosing of the first patient in a Phase 1/2 clinical trial for TRI-611, a novel investigational therapy for a specific type of lung cancer. The trial marks the clinical debut of a drug built on an innovative 'molecular glue' platform, a technology that aims to overcome one of modern cancer treatment's most persistent challenges: drug resistance.

The study will evaluate TRI-611 in patients with anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC), a subtype that often affects younger, non-smoking individuals. This new therapy represents a fundamentally different approach to fighting the disease, moving beyond simply inhibiting cancer-driving proteins to actively eliminating them from the body.

“Dosing of the first patient with TRI-611 marks an important milestone for TRIANA and for the ALK+ NSCLC patient community,” said Dr. Patrick Trojer, President and CEO of TRIANA, in a company statement. “This study reflects our commitment to treating diseases in entirely new ways by applying our molecular glue technology to highly relevant cancer targets.”

The Challenge of Resistance in ALK+ Lung Cancer

Non-small cell lung cancer is the most common form of the disease, and the ALK+ subtype, found in about 3-7% of NSCLC cases, is driven by a specific genetic rearrangement. This discovery paved the way for highly effective targeted therapies known as ALK tyrosine kinase inhibitors (TKIs). Drugs like Alectinib and Lorlatinib have transformed the prognosis for many patients by directly blocking the ALK fusion protein that fuels tumor growth.

However, this success is often temporary. For most patients, the cancer eventually evolves and finds ways to bypass the treatment, a phenomenon known as acquired resistance. This can happen through new mutations in the ALK gene itself, making it impervious to the inhibitor, or by activating entirely different signaling pathways to sustain growth. When this occurs, patients and their clinicians face dwindling options, underscoring a critical unmet need for new therapeutic strategies.

The high incidence of brain metastases in ALK+ NSCLC patients further complicates treatment, requiring drugs that can effectively cross the blood-brain barrier. The development of therapies that can overcome multiple resistance mechanisms and effectively treat the central nervous system remains a primary goal in the field.

A New Scientific Paradigm: The 'Molecular Glue' Approach

TRI-611 is not another inhibitor. It is a molecular glue degrader, representing a new class of medicine that works by co-opting the body's own cellular machinery for waste disposal. Instead of just blocking the ALK protein's active site, TRI-611 is designed to act as a matchmaker, 'gluing' the rogue ALK protein to an E3 ubiquitin ligase called cereblon.

This newly formed complex flags the ALK protein for destruction. The cell's natural disposal system, the proteasome, then recognizes this tag and completely eliminates the cancer-driving protein. This mechanism offers several potential advantages over traditional inhibitors. Because the drug acts catalytically—meaning one molecule of TRI-611 can trigger the destruction of many ALK protein molecules—it may be effective at lower doses and offer a more durable response. Furthermore, by binding to a site on the ALK protein that is different from the kinase active site targeted by TKIs, it has the potential to work even when the cancer has developed mutations that confer resistance to current therapies.

TRI-611 is an oral, small molecule designed to be highly selective and brain-penetrant, directly addressing the challenge of brain metastases. This approach of targeted protein degradation aims to fundamentally change the treatment paradigm, offering a way to eliminate the root cause of the cancer's growth rather than just suppressing its activity.

Inside the TRI-611 Clinical Trial

The global, first-in-human study is designed to rigorously assess TRI-611's potential. The Phase 1 portion will focus on safety and establishing an optimal dose. Critically, it will enroll ALK+ NSCLC patients who have already been treated with standard ALK TKI therapies, targeting the very population with the highest unmet need. This dose-escalation phase will evaluate the drug's safety, tolerability, and pharmacokinetic profile.

Following the dose-escalation phase, the Phase 2 portion of the trial will expand to further evaluate the efficacy and safety of TRI-611 across different patient cohorts. Researchers will be looking for preliminary signs of anti-tumor activity, such as tumor shrinkage, to provide early evidence of the drug's effectiveness.

“Despite progress in treatments, many patients continue to face limited options,” noted Dr. Caroline Germa, Chief Medical Officer of TRIANA. “This study represents an important step in our mission to develop innovative therapies that may ultimately improve outcomes for ALK+ NSCLC patients and their families.”

TRIANA's Strategic Bet on a Disruptive Platform

The initiation of this trial is not only a milestone for patients but also a key validation of TRIANA Biomedicines' strategy. The private Lexington-based company launched in 2022 with a focus on building a leading platform for discovering molecular glue degraders, a field attracting intense interest and investment across the biopharmaceutical industry.

TRIANA has secured substantial financial backing, raising $110 million in a Series A round and an oversubscribed $120 million Series B round from a syndicate of top-tier investors, including RA Capital Management, Atlas Venture, and Pfizer Ventures. This strong investor confidence underscores the perceived potential of its technology to address disease targets that have been difficult or impossible to drug with conventional methods.

The company has also forged strategic research collaborations with pharmaceutical giants Pfizer and Johnson & Johnson to discover novel molecular glue degraders, further validating its scientific platform. By advancing its first internally developed candidate, TRI-611, into the clinic, TRIANA is moving to translate its promising preclinical science into a tangible therapeutic that could one day offer new hope to patients battling resistant cancers.